Benefits and challenges of using PARP inhibitors to treat metastatic breast cancer

Kimberly Halla speaks to ecancer at ONS 2019 about the benefits and challenges for oncology nurses of using PARP inhibitors to treat metastatic breast cancer.

She outlines how PARP inhibitors, first used to treat ovarian cancer, have now been found to also be effective in treating metastatic breast cancer.

Kimberly also describes how beneficial PARP inhibitors are to the patient in terms of being able to take these oral therapies at home.

This programme has been supported by an unrestricted educational grant from Pfizer.